|Bid||4.90 x 1300|
|Ask||5.37 x 1100|
|Day's Range||4.86 - 5.14|
|52 Week Range||4.56 - 10.98|
|Beta (5Y Monthly)||0.06|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 12, 2021 - May 17, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||11.00|
A look at the shareholders of Dyadic International, Inc. ( NASDAQ:DYAI ) can tell us which group is most powerful...
By John Vandermosten, CFA NASDAQ:DYAI READ THE FULL DYAI RESEARCH REPORT 2020 Operational & Financial Results Dyadic International Inc. (NASDAQ:DYAI) released 2020 operational and financial results on March 30, 2021 and concurrently filed its Form 10-K with the SEC. A Phase I trial is planned in 2H:21 that will evaluate the safety of a C1-produced vaccine in human subjects. Following the
2 million at year-end 2020JUPITER, FL / ACCESSWIRE / March 30, 2020 / Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines, drugs and other commercial products at flexible commercial scales, today announced its financial results for 2020 and recent business highlights.